Thrombin-activatable fibrinolysis inhibitor

Thrombin-activatable fibrinolysis inhibitor
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Thrombin-activatable_fibrinolysis_inhibitor".

content

carboxypeptidase B2
Identifiers
Symbol	CPB2
Entrez	1361
HUGO	2300
OMIM	603101
RefSeq	NM_001872
UniProt	Q96IY4
Other data
Locus	Chr. 13 q14.11

Thrombin-activatable fibrinolysis inhibitor (TAFI), also known as plasma carboxypeptidase B2 is a recently described plasma zymogen that, when exposed to the thrombin-thrombomodulin complex, is converted by proteolysis at Arg92 to a basic carboxypeptidase (TAFIa or activated TAFI) that inhibits fibrinolysis.

Fibrinolysis (simplified). Blue arrows denote stimulation, and red arrows inhibition.

TAFI is produced by the liver.

v • d • e Proteins: coagulation

Coagulation factors	primary hemostasis: vWF intrinsic pathway: HMWK/Bradykinin - Kallikrein - Hageman / FXII - FXI - FIX - FVIII extrinsic pathway: Tissue factor / FIII - FVII common pathway: FX - FV - (Pro)thrombin / FII, Fibrin / FI - FXIII

Coagulation inhibitors	Antithrombin (inhibits II, IX, X, XI, XII) - Protein C (inhibits V, VIII)/Protein S (cofactor for protein C) - Protein Z (inhibits X) - ZPI (inhibits X, XI) - TFPI (inhibits III)

Fibrinolysis	Plasmin - tPA/urokinase - PAI-1/2 - α2-AP - α2-macroglobulin - TAFI

This medical article is a stub. You can help Wikipedia by expanding it.

Your Ad Here